Improvement of inflammatory dermatoses severity and quality of life in patients treated with a betamethasone valerate plaster (LIBERE study). (2nd January 2016)

• Record Type: Journal Article
• Authors: Maccari, Francois
• Is Part Of: Journal of dermatological treatment. Volume 27(2016)Supplement 1
• Page Start: 59
• Page End: 63
• Publication Date: 2016-01-02
• Subjects: Betamethasone valerate 0.1% -- dermatoses -- DLQI -- non-interventional study -- PGA -- plaster; Skin -- Diseases -- Treatment -- Periodicals; Skin Diseases -- drug therapy -- Periodicals; Skin Diseases -- therapy -- Periodicals; 616.5
• DOI: 10.3109/09546634.2015.1035692
• Languages: English
• ISSNs: 0954-6634

Abstract

Abstract: Background : A ready to use betamethasone valerate 0.1% (BMV) dressing was effective and well-tolerated by patients receiving chronic plaque psoriasis treatment. Objective : Collect data related to BMV dressing used in the context of market authorization. Methods : An observational, prospective study, including 258 patients with a maximum 4-weeks-treatment of inflammatory dermatosis with BMV 2.25 mg plaster was performed. The prescription pattern was described and the disease severity assessed using a Physician Global Assessment (PGA). Patient satisfaction as well as their quality of life (DLQI) were evaluated. Clinical evaluation was performed before and after the treatment. Results : The DLQI scores improved from 10.0 ± 5.4 to 3.5 ± 3.5 points ( p < 0.0001) and PGA decreased from 12.5 ± 3.1 to 4.2 ± 3.0 points ( p < 0.0001). The highest DLQI and PGA improvement was reported for the eczema group. Subjects reported the test dressing was better than prior therapies with 93.5% very satisfied and 90.4% satisfied. Conclusions : The BMV dressing is well-tolerated and effective in the treatment of inflammatory dermatoses, improving both the objective signs of the disease as well as patients' quality of life.